OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has demonstrated significant progress in developing innovative therapeutics for inflammatory eye diseases and chronic pain, particularly through its promising drug candidates, Urcosimod and OK-101. Both products have shown favorable safety and tolerability profiles along with statistically significant improvements in key symptoms associated with dry eye disease, including stinging, burning, and ocular pain. The potential of these treatments to address neuropathic corneal pain positions OKYO Pharma favorably within the biopharmaceutical market, suggesting strong growth prospects as they advance through clinical trials.

OKYO Pharma faces significant risks that could adversely affect its financial performance, including the potential failure of its lead product, OK-101, in clinical trials and the subsequent inability to secure regulatory approval in the U.S. The company reported a net loss of $2.7 million or $0.08 per share for the six months ending September 30, 2024, indicating ongoing financial challenges. Additionally, there are concerns regarding the product's commercial viability due to factors such as market size, penetration rate, competition, and the threat of shareholder dilution.